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Abstract 
Background: With rising health care costs and the diversity of scientific and clinical information available to health 
care providers it is essential to have methodologies that synthesize and distill the quality of information and make it 
practical to clinicians, patients and policy makers. Too often research synthesis results in the statement that “more and 
better research is needed” or the conclusions are slanted toward the biases of one type of stakeholder. Such conclu-
sions are discouraging to clinicians and patients who need better guidance on the decisions they make every day.
Method: Expert panels are one method for offering valuable insight into the scientific evidence and what experts 
believe about its application to a given clinical situation. However, with improper management their conclusions can 
end up being biased or even wrong. There are several types of expert panels, but two that have been extensively 
involved in bringing evidence to bear on clinical practice are consensus panels, and appropriateness panels. These 
types of panels are utilized by organizations such as the National Institutes of Health, the Institute of Medicine, RAND, 
and other organizations to provide clinical guidance. However, there is a need for a more cost effective and efficient 
approach in conducting these panels. In this paper we describe both types of expert panels and ways to adapt those 
models to form part of Samueli Institute’s Scientific Evaluation and Research of Claims in Health Care (SEaRCH™) 
program.
Discussion: Expert Panels provide evidence-based information to guide research, practice and health care decision 
making. The panel process used in SEaRCH seeks to customize, synthesize and streamline these methods. By mak-
ing the process transparent the panel process informs decisions about clinical appropriateness and research agenda 
decisions.
Keywords: Clinical expert panel, Research expert panel, Policy expert panel, Patient expert panel, Subject matter 
experts, Methodology, Appropriateness, Scientific evaluation and review of claims in health care
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Background
When attempting to develop evidence-based medicine, 
health professions face several challenges in trying to 
base their practices on evidence. One source of informa-
tion is scientific evidence derived from research stud-
ies. However, since a single study is seldom definitive, a 
systematic review of the numerous studies published in 
the literature is preferable. Systematic reviews of the lit-
erature provide a method of assessing the quality of each 
individual study [1, 2], as well as assessing the overall 
level of evidence based on the entire published literature 
for a particular intervention in a given population [2–5]. 
In a separate article in this series of articles we describe a 
rapid and reliable way of getting sound evidence through 
systematic reviews called the Rapid Evidence Assessment 
of the Literature (REAL©) [6]. However, while clinical 
research, systematic reviews and their publications are 
necessary, they are not sufficient to ensure that the rel-
evant evidence has been properly assembled or that it 
can influence practice and clinical decision making. This 
may occur because of the paucity of studies available, 
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because of the poor quality of the studies, because of the 
restricted nature of the populations in clinical studies or 
because of the impossibility of doing the studies for either 
ethical issues or methodological or resource reasons 
[6, 7]. The result is that much of health care occurs in a 
clinical space in which the evidence is indeterminate or 
uncertain. When good evidence does not exist to guide 
practice, clinicians must base their approach on their 
own clinical intuition, on what they were taught in their 
training or on what the experts recommend. However, 
such approaches lack transparency and rigor and are 
often fraught with error. Coulter has termed this “thera-
peutic anarchy” where in effect each clinician does his/
her own thing or the market drives what is done rather 
than patient needs and preferences [7, 8]. The situation is 
even worse for patients who may not even have the basic 
knowledge or experience on how to interpret evidence 
but are also asked to make decisions about treatment 
choices and preferences.
Expert panels
One approach that has emerged to overcome this prob-
lem has been the use of expert panels (EP). While in 
systematic reviews the opinion of experts is considered 
at the bottom of the evidence hierarchy, in expert pan-
els, which combine evidence and clinical acumen, the 
opinions are made transparent and subjected to criti-
cal appraisal. This overcomes the major objection to the 
opinion of experts vs. systematic reviews and has the 
additional value of allowing the introduction of informa-
tion closer to clinical practice and a better interface with 
research evidence.
Samueli Institute uses the following expert panels: 
a Clinical Expert Panel (CEP), and a Research Expert 
Panel (REP), with others designed for policy (PoEP) and 
patient expert panel (PaEP) decisions, in development. 
These types of panels form a part of the Scientific Evalu-
ation and Review of Claims in Health Care (SEaRCH™) 
process. [6] They draw on the best in existing models of 
expert panels, but differ in that they are designed to com-
plement the evidence process in the SEaRCH program to 
better clarify both research agenda needs and facilitate 
practice decisions. They also differ from other EPs in that 
the process for doing them is structured and streamlined 
to ensure they can be conducted rapidly and in an objec-
tive and cost effective manner. Furthermore, they can be 
customized in response to a client’s needs.
Samueli Institute’s EP processes have drawn from three 
methods developed over time to deal with the application 
of evidence to practice. These are the National Institutes 
of Health Consensus Development Conference (NIH 
CDC), the Institute of Medicine (IOM) report process 
and the RAND Expert Panel process. Because we draw 
on these three methods they will be described briefly in 
what follows.
NIH consensus panels
The National Institute of Health (NIH) consensus devel-
opment conference method for resolving evidence judg-
ment issues was begun in 1977 by NIH as a method by 
which the scientific community could bring relevant 
research to bear on the quality of health care [8–10]. The 
purpose of the NIH Consensus Development Confer-
ence (CDC) is to bring clinical practice more in line with 
research and so improve the quality of care. “To achieve 
this, the focus is on the scientific community bring-
ing to the attention of the health professions the results 
of research and the impact on the quality of care.” [8, 9] 
Given its purpose the membership of the NIH panels 
favors research experts in both the clinical and related 
aspects of the topic.
NIH panels focused largely on questions of efficacy and 
safety [10], and are intended to resolve scientific issues 
(controversies) [11]. However, the issues chosen have 
to be resolvable by evidence. There is testimony from 
experts, audience participation and the end product of 
the panel is consensual statements (i.e. 100 % agreement). 
A panel of experts is chosen and reviews the evidence for 
or against a procedure. Recently, panels are provided with 
a systematic literature review and the original literature. 
Over 2 days panelists also hear testimony from experts. 
These hearings are open to audience participation who 
may also comment. At the end of this process the panel 
is then cloistered until the final consensual recommenda-
tions are completed. These are then issued publicly. The 
topics chosen can either be disease based (e.g. breast 
cancer) or procedure based (e.g. mammography). The 
focus is on the state of the science rather than the state 
of current practice. Commentators have described the 
NIH process as a combination of three models: the judi-
cial process using testimony and a jury; a scientific meet-
ing where research evidence is presented; and the town 
meeting where interested citizens can make comments 
[9, 10]. Ultimately, however, the recommendations are 
made by a select few with scientific expertise and made 
behind closed doors. Consensus panels may also com-
ment on the state of the science and make recommenda-
tions about both present and future research needs.
There are, however, several challenges which limit the 
usefulness of the NIH Consensus Development Panels. 
If the focus is only on those issues that can be resolved 
by scientific evidence, it is necessarily confined to those 
issues with scientific support. Unfortunately, within the 
field of health care, many of the most problematic issues 
cannot be resolved by evidence alone. In such a situation 
the NIH CDC is forced to report simply on the state of 
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the science. In addition, the judgment processes used for 
the final conclusions are also done behind closed doors 
and so are not completely transparent.
The NIH panel places a premium on research find-
ings, and gives less weight to clinical experience or acu-
men (although in the testimony phase it may hear this). 
This undermines the credibility of the NIH panels with 
the very persons it seeks to influence—practitioners and 
patients. Additionally, the panels favor largely scien-
tific (not clinical experts) in both the clinical and related 
aspects of the topic [8, 9]. Related to this, they focus on 
efficacy and not effectiveness and on the state-of-art 
practices and not usual practice. This makes their guide-
lines less useful to practitioners. This panel is an expen-
sive process which means it cannot be repeated very 
often. Where technology is transforming practice rapidly, 
the findings can become obsolete very quickly. Consen-
sus statements are considered by NIH to be historical 
documents after 5 years and they do not recommend that 
decisions be based on these statements after that time. 
Unfortunately, updates to these statements are rarely 
conducted, due to the costs of conducting the compre-
hensive systematic reviews and the rarity of gathering an 
NIH panel. This is limiting in areas of health care that are 
changing rapidly, where answers about particular clinical 
procedures are needed expediently, and where it is recog-
nized that evidence-based clinical decision-making needs 
to be informed via timely updates and re-assessment of 
the literature [13]. Research by RAND has shown that the 
impact of the NIH panels on care is not strong in chang-
ing physician behavior [10–12].
Another limiting factor of NIH panels is that they are 
consensus-based, and while minority reports are pos-
sible, participants are strongly encouraged to agree on 
assessments and recommendations. Such consensus 
panels may be more prone to bias from dominant panel 
members [11]. The recommendations include only those 
for which there is consensus, and the panels are clois-
tered until such consensus is met [12]. This often means 
that the result is the “lowest common denominator”. The 
evidence for the clinical impact of the NIH panels on 
changing behavior of health care providers has not been 
strong. The emphasis on efficacy rather than effectiveness 
and not on the state of the current practice has limited 
the relevance of the panel findings for a broader health 
care audience.
In situations where the evidence is insufficient to derive 
consensus statements or as part of the consensus panel 
for clinical practice, a state of the science special panel 
can be created. This panel is also further limited by the 
relative lack of transparency and specificity related to 
gap assessment and research recommendations. Little 
systematic information is given on how group decisions 
are made regarding literature gap assessment, includ-
ing the relevance of a particular gap for clinical practice 
or policy, or the types of research designs best suited to 
address specific gaps. Finally, as noted by the Institute of 
Medicine (IOM), many expert panels do not make a clear 
distinction between the quality of evidence vs. strength 
of recommendations. While the NIH State-of-the-Sci-
ence Panels are ostensibly run when there is a perception 
that the evidence base is “weaker”, the methods used in 
assessing the quality of evidence may vary and strength 
of recommendations often varies. Recommendations 
from these “State-of- the-Science” panels are not pre-
sented based on the relevance of a particular gap in terms 
of research, practice, or policy.
Institute of medicine reports
The Institute of Medicine (IOM) also produces reports 
that often summarize evidence and make recommenda-
tions about practice and research. While their methods 
can vary, the basic approach is similar to the NIH CDC 
in that they pick scientific experts, receive outside input 
and sequester the participants and seek consensus when-
ever possible. Unlike the NIH CDC, the panels usually 
meet several times and have more time for discussion 
and analysis. In addition, the reports are longer and more 
thoroughly developed. However, despite a recent IOM 
report on criteria for systematic reviews and guidelines, 
each panel does not yet always conduct or rely on sys-
tematic reviews and their processes are sometimes even 
less transparent than those of NIH [12, 13]. Their impact 
on clinical practice also varies. While IOM works hard to 
reduce clear conflict of interest of panel members, they 
do not structure the conduct of any SRs done and the 
experts in a way to prevent bias during the assessment 
and consensus process. Thus, the bias of panel members 
with more dominant voices can influence the outcome.
RAND expert panels for appropriateness of care
The RAND method has been extensively described 
elsewhere in the literature. One of its essential features 
vis-a vis the NIH or IOM approaches is that the RAND 
approach is oriented less to scientific experts and more 
to clinical experts [8, 9]. In addition, the RAND process 
has carefully evaluated the optimum process for creat-
ing diverse and multi-stakeholder input, allowing for bias 
reduction and wider audience relevance.
Coulter [13, 14] has described the RAND panel in pre-
vious publications and this will be drawn on here [14, 
15]. The process has a specific way of managing the panel 
to address some of the limitations of those previously 
described. In a RAND panel nine experts are chosen. The 
members reflect a spectrum of clinicians and academics, 
so that any given specialty does not dominate the panel 
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(five academically based and four practicing clinicians). 
In addition, the RAND expert panel evaluation of the 
evidence process departs from that of the NIH CDC and 
IOM. The main differences between these and the RAND 
panel process are described below.
First, in a RAND panel an extensive review of the lit-
erature is conducted and a systematic review written (a 
meta-analysis if this is possible, but a synthesis if it is not) 
[23]. In the RAND clinical appropriateness panel pro-
cess, research staff (with input from clinical expertise) 
then creates a set of possible clinical indications to which 
the evidence might be applied. These indications cat-
egorize patients in ways that they usually present to the 
clinic. This includes such things as their symptoms, past 
medical history, the results of previous diagnostic tests 
and patient preferences. “The objective is to create lists 
that are detailed, comprehensive, and manageable. They 
must be detailed enough so that the patients covered by 
the category are relatively homogeneous so that the pro-
cedure would be equally appropriate for all of them. To 
be comprehensive they must include all the indications 
for doing the procedure that occur in practice. However, 
they must be short enough that the panelists can com-
plete them within a reasonable space of time.” [8, 9].
After these lists are compiled, the process uses a modi-
fied Delphi method where the indications created are 
sent to the nine panelists along with the literature synthe-
sis. The panelists then independently rate the appropri-
ateness of the procedure based on the evidence from the 
literature review and their clinical experience. The ratings 
for appropriateness are from 1 to 9, with 1 representing 
extremely inappropriate and 9 extremely appropriate. 
Appropriate care is defined as when “the expected health 
benefit to the patient (relief of symptoms, improved 
functional capacity, reduction of anxiety, etc.) exceed 
expected health risks (pain, discomfort, time, cost, etc.) 
by a sufficiently wide margin that the procedure is worth 
doing” [14, 15]. The panelists are instructed to evaluate 
the risks and benefits based on commonly accepted best 
clinical practice for the year in which the panel is con-
ducted. Considering an average group of patients with 
each listed indication, presenting to an average practi-
tioner in the US, the ratings should reflect the panelist’s 
own best clinical or expert judgment. In this way the 
judgments are a combination of evidence from the lit-
erature and clinical acumen or experience with realistic 
variations as they often happen in the clinic. This forms 
a bridge from evidence to practice in a more realistic way 
than simple evidence summaries do, but with a more 
systematic and balanced process than individual clinical 
opinion.
These ratings are quantitatively summarized by the 
research staff. Then, in a second round of ratings the 
panelists are brought together in a face-to-face meeting. 
Each panelist is shown his/her rating for each indication, 
and the distribution of the ratings of the panel as a whole 
is presented for each indication. Individual panelists 
must reconsider their judgment and although they are 
not forced to defend it in most cases, where the individ-
ual does differ from the group, he/she will usually do so 
or at least explain the logic or evidence for that position. 
Following the discussion, the panelists re-rate the appro-
priateness of the procedure again. From the second rat-
ing, it is possible to determine the degrees of agreement 
in the panel, and to calculate the average median ratings, 
and the average dispersion measures for the procedures. 
Consensus is not required. However, in most instances 
the dispersion decreases during the second rating as the 
panelists come closer to a consensus. Once the work of 
the expert panel is completed, the team then compiles a 
set of indications for performing a procedure based on 
the evidence and their clinical experience, which can 
then be used to compare to actual practice. This allows 
researchers to calculate a rate of appropriate/inappropri-
ate care present in practice.
In the RAND panels, consensus is not required but its 
degree is measured. RAND has utilized two approaches 
to measure consensus. In the first there is consensus 
if all raters’ responses fall within one of the three point 
ranges of the scale (i.e. 1, 2, 3; 4, 5, 6; 7, 8, 9). This would 
mean all the raters agreed that the procedure should not 
be performed (1, 2, 3); they agreed that it was question-
able or uncertain (4, 5, 6); or, they agreed that it should 
be performed (7, 8, 9). The second method is to define 
agreement if all the ratings fell within any 3 point range. 
Furthermore, agreement can be determined using both 
methods but by rejecting one extreme high or low rat-
ing. Similarly, disagreement can be calculated using two 
methods; if at least one rater chose a 1 and one chose 
a 9; or if at least one rater fell in the lowest three point 
region and at least one in the highest. As with disagree-
ment, the extreme ratings can be discarded. A procedure 
can be judged inappropriate if its median rating is in the 
range 1–3, and without disagreement; uncertain if the 
median rating is in the range 4–6, and appropriate if it is 
7–9, without disagreement. Finally, the outcome can also 
be that the panelists disagreed on the proper rating (they 
were indeterminate) [13–16].
A unique feature of the RAND appropriateness panel is 
the amount of research that has been done on its reliabil-
ity and validity, making the RAND panel process, unlike 
other expert panel processes, truly evidenced-based. 
For validity of the RAND appropriateness panel, studies 
have examined the relationship between ratings and the 
literature [6], face and content validity [16, 17] and con-
struct validity [18, 19]. Studies have looked at test–retest 
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reliability [20], compared panels occurring in different 
countries on the same procedures [21], compared pan-
els occurring at different times [20], and investigated the 
impact of panel membership on the judgments of appro-
priateness [17]. These studies show that, when these steps 
are applied, extreme variation across the panels does 
not occur. The first formal test of reproducibility of the 
RAND panels [20] tested the reliability of three parallel 
panels for two procedures, hysterectomy and coronary 
revascularization, conducted within the same time frame. 
Comparing the reproducibility of the panels with what 
physicians do daily, the study concluded that the RAND 
method is much less variable than physicians making 
independent decisions. Coulter et al. [17] have compared 
the panel ratings of a multidisciplinary panel versus an all 
specialty panel for spinal manipulation for low back pain 
and shown that those who use this procedure are more 
likely to rate it as appropriate for more conditions than 
those who do not [7, 17–22].
SEaRCH™ Expert Panels
The SEaRCH Expert Panel Process draws heavily on the 
work done at NIH, IOM and RAND. The process inte-
grates the most reliable and useful aspects of these pan-
els. The desire to create a streamlined approach was 
driven by the need to reduce cost and create more effi-
cient and transparent expert panels.
One example of streamlining is to have expert pan-
elists utilize the online technology database to enter data 
related to appropriateness ratings. Another is to hold 
meetings via teleconference, which allows for reduced 
costs as well as the inclusion of key expert panelists that 
otherwise may not be able to attend an in-person meet-
ing. This also allows for the overall panel process to 
happen more expediently and to be more inclusive of 
the right experts for balance. In addition, it allows for a 
greater variety of panel types to be developed to serve 
different purposes, such as panels focused on policy and 
patient preferences.
Currently, the SEaRCH Expert Panel Process (SEPP) 
uses expert panels for two primary purposes –clini-
cal appropriateness and research agendas. A Clinical 
Expert Panel (CEP) is used to determine when care is 
appropriate or inappropriate combining both evidence 
and clinical acumen, similar to the RAND process. A 
Research Expert Panel (REP) is designed to examine 
the state-of-science and to identify and prioritize gaps 
in the scientific evidence vis-à-vis practice. Both the 
CEP and REP are used particularly in areas where the 
evidence is either lacking in quality or insufficient to 
determine appropriate care using usual consensus or 
guideline processes. While the two expert panels differ, 
the processes they use are similar and will be described 
jointly below.
SEaRCH Expert Panel Process (SEPP)
A request for a SEaRCH Expert Panel Process (SEPP) 
typically comes from an outside person or group who 
needs a balanced and objective way to make research 
or clinical recommendations on a particular topic. The 
requestor often seeks to obtain an evidence-based, expert 
judgment to help determine the appropriateness for 
clinical use of, or develop the research needs for, a prod-
uct, practice, program or policy. In the case of a clinical 
expert panel (CEP), the requestor seeks recommenda-
tions for an intervention within a given setting or rec-
ommendations around a particular treatment approach 
in various settings. In the case of a research expert panel 
(REP), the requestor seeks specific research recommen-
dations based on current gaps in the evidence and may 
include an assessment of available resources and readi-
ness to conduct such research. The following describes 
the steps in the SEaRCH Expert Panel Process (SEPP). 
Figure 1 provides a flow chart of the CEP process.
The first step of the SEPP is for an Expert Panel Man-
ager to meet with the client to create and refine the ques-
tion to be answered. This meeting also examines the 
focus of the other integrated SEaRCH components such 
as the REAL (Rapid Evidence Assessment of the Litera-
ture) which is a streamlined, reliable, systematic review 
process; [22, 23] and the Claim Assessment Profile (CAP) 
[23, 24], which provides a detailed descriptive evalu-
ation of the intervention (product, practice, program 
or policy) and claim (efficacy, effectiveness, efficiency, 
relevance, cost and outcome). The CAP and REAL pro-
cesses involved in SEaRCH are described in the compan-
ion pieces in this issue. Next, a balanced team is created 
for the successful conduct of the panel. The selection of 
panel members is key for obtaining valid judgments from 
a panel. Panelists are always selected to ensure no conflict 
of interest in the area. They are also selected to provide a 
diversity of experience and knowledge within the panel. 
The SEPP process uses specific criteria to select the most 
qualified panel members.
As stated earlier, one of the benefits of the SEaRCH 
model is the communication that occurs between the 
description, evidence and judgment components (the 
CAP, REAL and SEPP, respectively) needed to answer 
important health information questions. For example, 
using the REAL process for informing the Expert Panels 
provides a systematized assessment of research quantity 
and quality. For the clinical expert panel, specific SMEs 
develop the clinical scenarios that will be rated by the 
panelists. Once the EP team and panel members have 
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been established and the clinical scenarios created, the 
actual panel process begins.
Each panelist integrates information from the REAL 
and/or CAP evidence with their own clinical judgment 
for each scenario. They rate the appropriateness of use of 
the intervention for each scenario and enter their ratings 
into an online database. The use of the database allows 
for less error, more opportunity for statistical review and 
a much faster turnaround of results for phase II.
The second phase of the CEP consists of all nine pan-
elists meeting face to face, either in person or through 
virtual means to review their clinical appropriateness rat-
ing scores and discuss them among the group. After the 
panel discussion, panelists are asked to re-rate the sce-
narios using the online database. The computerized pro-
gram can be used to tabulate the new re-rated scenarios.
Conducting research expert panels
As the flow chart in Fig. 2 demonstrates, the initial steps 
in the research panel are similar for the research and 
clinical expert panels. The following methodological pro-
cesses focus on the specifics of conducting the Research 
Expert Panel.
Similar to the Clinical EP, the Research EP is a two-
phased process. However, in this case, initial ratings 
entered in the online technology database are not 
based on appropriateness of clinical care, but rather on 
elucidating and clarifying research gaps, as well as identi-
fying research designs to address the most relevant gaps.
Similar to the Clinical EP, the Research EP member 
integrates his/her knowledge and expertise with the 
available evidence from the REAL and/or CAP, and then 
enters this information into a computerized database. 
The initial ratings provided by the research expert pan-
elists help to systematize and make transparent specific 
recommendations on research directions in particular 
gap areas. In the case where research recommendations 
are being made specifically for an institution that wishes 
to carry out a research project, tailored recommenda-
tions also are based on the available resources for that 
institution (when explicated through the CAP). The pro-
cess for convening the Research Expert Panel in Phase II 
is similar to the Clinical Expert Panel.
The goal of the research expert panel meeting, how-
ever, is for the panelists to discuss areas where they may 
disagree on gaps and next research priorities. As with the 
clinical expert panel, after the panel discussion, panelists 
are then asked to re-rate the research form. Panelists 
input their ratings in the database which tabulates the 
scores.
The last phase of the process is to summarize and 
deliver the panel recommendations in a report with 
quantified ratings. Recommendations and specific con-
tent of each summary report will vary depending on the 
Fig. 1 Basic steps in a clinical expert panel (CEP)
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type of panel (research vs. clinical appropriateness) and 
the question(s) that the client is seeking to answer. For 
these panels, the summary includes an in depth descrip-
tion of the EP methodology and recommendations based 
upon the findings.
Panel variations: making panels more patient 
centered
It is important to note that this panel model can be modi-
fied to address questions on multiple issues related to 
health care such as policy implementation and patient-
centeredness. For example, a Policy Expert Panel (PoEP) 
is a derivative of the Research Expert Panel and focuses 
on making evidenced based policy judgments (payment, 
coverage, scope of practice) to direct implementation of a 
practice claim. In fact, this panel is often used to explore 
direct implementation issues even when a policy issue is 
not a factor.
One of the biggest challenges in all panel processes is 
that they have difficulty obtaining patient input early and 
continuously in the decision making. Usually, patient rep-
resentatives are placed on advisory boards where input 
comes late in the decision making process. In addition, 
patients may feel intimidated or lost when on panels 
with scientists and clinical experts, especially if they are 
not trained or comfortable executing their role and using 
the panel methodology. The Samueli SEPP has patients 
and patient interest groups involved in every phase of the 
process,. It may even be deemed appropriate to convene 
a Patient-only Expert Panel (PoEP) to achieve a complete 
patient perspective. Patients can be incorporated into 
panels in various ratios such as equal (1:1:1 with scien-
tists and clinicians) or weighted toward patients (2:1:1). In 
addition, use of the anonymous Delphi and virtual meet-
ing processes can further empower patient input more 
deeply in judging either clinical or research relevance, 
making both methods more patient-centered. The REAL 
review process also trains all potential panel members 
(no matter their expertise) in how to use the results of a 
systematic review. Special training of the patient panel 
members and of panel moderators also enhances commu-
nication and input from the patient’s perspective [23, 25].
Conclusions and discussion
There is an essential need for evidence-based informa-
tion to guide research, practice and health care decision 
making. Expert panels contribute to evidence-based 
decision making in both research and practice by closing 
the gap between the usual evidence summaries and the 
needs of clinicians, policy makers, patients and research-
ers for using such evidence in daily decisions. There is a 
clear need for more transparent, systematized, and effi-
cient processes for expert panels, especially in terms of 
providing recommendations. This process seeks to fill 
those gaps. As part of the SEaRCH program, Samueli 
Institute streamlined an expert panel process that was 
Fig. 2 Basic steps in a research expert panel (REP)
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driven by the need for cost effective, efficient and trans-
parent approaches to addressing health care needs. It is 
designed to expand diverse stakeholder input into the 
research judgment process. This allows for easier delivery 
of expert opinion and patient input for making decisions 
about research priorities and clinical appropriateness. 
This methodology is integrated with other SEaRCH com-
ponents such as the Rapid Evidence Assessment of the 
Literature (REAL) and the Claims Assessment Profile 
(CAP). This methodology is still new and will need to be 
validated in the future. The use of information from these 
three evidence based components, will allow for more 
customized, expedient and evidence-based recommen-
dations on therapeutic claims of interest.
The expert panel process is the final step in the inte-
grated SEaRCH process described in this series of arti-
cles. It improves the link between research evidence, 
research agendas, real world practice decisions and 
patient needs and preferences. Together these integrated 
strategies allow development of true evidence-based 
health care.
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